Selected mice models based on APP, MAPT and presenilin gene mutations in research on the pathogenesis of Alzheimer's disease;Wybrane mysie modele oparte na mutacji genów APP, MAPT oraz presenilin wykorzystywane w badaniach nad patogeneza̧ choroby alzheimera

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 66, Issue , 2012, Pages 415-430

  Wiȩdłocha, Magdalena ^a   Stańczykiewicz, Bartłomiej ^a,b   Jakubik, Marta ^a,b   Rymaszewska, Joanna ^a,b  

^a Innowacyjne Technologie Produkcji Biopreparatów na Bazie Nowej Generacji jaj OVOCURA   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Alzheimer's disease; Animal models; Behavioral tests; Transgenic mice

Indexed keywords

EID: 84867925904     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1001098     Document Type: Review

References (155)

1. Adlard P. A., Perreau V. M., Pop V., Cotman C. W.: Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci., 2005;25:4217-4221
2. Alldred M. J., Duff K. E., Ginsberg S. D.: Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol. Dis., 2012;45:751-762
3. Allen B., Ingram E., Takao M., Smith M. J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P. C., Atzori C., Migheli A., Crowther R. A., Ghetti B., Spillantini M. G., Goedert M.: Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci., 2002;22:9340-9351
4. Alzheimer Research Forum. http://www.alzforum.org/res/com/tra/default.asp (19.04.2012)
5. Ambrée O., Touma C., Görtz N., Keyvani K., Paulus W., Palme R., Sachser N.: Activity changes and marked stereotypic behavior precede Aβ pathology in TgCRND8 Alzheimer mice. Neurobiol. Aging, 2006;27:955-964
6. Andorfer C., Acker C. M., Kress Y., Hof P. R., Duff K., Davies P.: Cellcycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci., 2005;25:5446-5454
7. Andorfer C., Kress Y., Espinoza M., de Silva R., Tucker K. L., Barde Y. A., Duff K., Davies P.: Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem., 2003;86:582-590
8. Arendash G. W., King D. L.: Intra-and intertask relationships in a behavioral test battery given to Tg2576 transgenic mice and controls. Physiol. Behav., 2002;75:643-652
9. Arendash G. W., King D. L., Gordon M. N., Morgan D., Hatcher J. M., Hope C. E., Diamond D. M.: Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res., 2001;891:42-53
10. Arispe N., Diaz J. C., Simakova O.: Aβ ion channels. Prospects for treating Alzheimer's disease with Aβ channel blockers. Biochim. Biophys. Acta, 2007;1768:1952-1965
11. Arnold S. E., Hyman B. T., Flory J., Damasio A. R., Van Hoesen G. W.: The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex, 1991;1:103-116
12. Ashe K. H.: Learning and memory in transgenic mice modeling Alzheimer's disease. Learn. Mem., 2001;8:301-308
13. Avila J., Lucas J. J., Perez M., Hernandez F.: Role of tau protein in both physiological and pathological conditions. Physiol. Rev., 2004;84:361-384
14. Baloyannis S. J., Costa V., Michmizos D.: Mitochondrial alterations in Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen., 2004;19:89-93
15. Bartoszewska M.: Molecular mechanisms of Alzheimer's disease. Postȩpy Biol. Kom., 2008;35:333-350
16. Billings L. M., Oddo S., Green K. N., McGaugh J. L., La Ferla F. M.: Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron, 2005;45:675-688
17. Bitner R. S., Markosyan S., Nikkel A. L., Brioni J. D.: In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology, 2011;60:460-466
18. Bondolfi L., Calhoun M., Ermini F., Kuhn H. G., Wiederhold K. H., Walker L., Staufenbiel M., Jucker M.: Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci., 2002;22:515-522
19. Braak H., Braak E.: Pathology of Alzheimer's disease. W: Neurodegenerative Diseases, D. B. Calne (red.), 1994;35:585-613
20. Braff D., Stone C., Callaway E., Geyer M., Glick I., Bali L.: Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology, 1978;15:339-343
21. Brody D. L., Holtzman D. M.: Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci., 2008;31:175-193
22. Brody D. L., Holtzman D. M.: Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury. Exp. Neurol., 2006;197:330-340
23. nd edition. red. Buccafusco J. J., Boca Raton (FL): CRC Press., 2009
24. Calhoun M. E., Wiederhold K. H., Abramowski D., Phinney A. L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M.: Neuron loss in APP transgenic mice. Nature, 1998;395:755-756
25. Chai X., Wu S., Murray T. K., Kinley R., Cella C. V., Sims H., Buckner N., Hanmer J., Davies P., O'Neill M. J., Hutton M. L., Citron M.: Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J. Biol. Chem., 2011;286:34457-34467
26. Chapman P. F., Falinska A. M., Knevett S. G., Ramsay M. F.: Genes, models and Alzheimer's disease. Trends Genet., 2001;17:254-261
27. Chapman P. F., White G. L., Jones M. W., Cooper-Blacketer D., Marshall V. J., Irizarry M., Younkin L., Good M. A., Bliss T. V., Hyman B. T., Younkin S. G., Hsiao K. K.: Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci., 1999;2:271-276
28. Chauhan N. B., Siegel G. J., Lichtor T.: Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Aβ antibody into the third ventricle of TgCRND8 mice. J. Neurosci. Res., 2004;78:732-741
29. Chen G., Chen K. S., Knox J., Inglis J., Bernard A., Martin S. J., Justice A., McConlogue L., Games D., Freedman S. B., Morris R. G.: A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature, 2000;408:975-979
30. Cheng I. H., Palop J. J., Esposito L. A., Bien-Ly N., Yan F., Mucke L.: Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med., 2004;10:1190-1192
31. Chishti M. A., Yang D. S., Janus C., Phinney A. L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P. E., Carlson G. A., George-Hyslop P. S., Westaway D.: Earlyonset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem., 2001;276:21562-21570
32. Clark L. N., Poorkaj P., Wszolek Z., Geschwind D. H., Nasreddine Z. S., Miller B., Li D., Payami H., Awert F., Markopoulou K., Andreadis A., D'Souza I., Lee V. M., Reed L., Trojanowski J. Q., Zhukareva V., Bird T., Schellenberg G., Wilhelmsen K. C.: Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. USA, 1998;95:13103-13107
33. Clinton L. K., Billings L. M., Green K. N. Caccamo A., Ngo J., Oddo S., McGaugh J. L., La Ferla F. M.: Age-dependent sexual dimporphism in cognition and stress response in the 3xTg-AD mice. Neurobiol. Dis., 2007;28:76-82
34. Corcoran K. A., Lu Y., Turner R. S., Maren S.: Overexpression of hAP-Pswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn. Mem., 2002;9:243-252
35. Del Vecchio R. A., Gold L. H., Novick S. J., Wong G., Hyde L. A.: Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci. Lett., 2004;367:164-167
36. De Mattos R. B., Bales K. R., Cummins D. J., Paul S. M., Holtzman D. M.: Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science, 2002;295:2264-2267
37. Dineley K. T., Xia X., Bui D., Sweatt J. D., Zheng H.: Accelerated plaque accumulation, associative learning deficits, and up-regulation of α 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem., 2002;277:22768-22780
38. Dodart J. C., Bales K. R., Gannon K. S., Greene S. J., De Mattos R. B., Mathis C., De Long C. A., Wu S., Wu X., Holtzman D. M., Paul S. M.: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci., 2002;5:452-457
39. Dodart J. C., Mathis C., Saura J., Bales K. R., Paul S. M., Ungerer A.: Neuroanatomical abnormalities in behaviorally characterized APP (V717F) transgenic mice. Neurobiol. Dis., 2000;7:71-85
40. Dodart J. C., Meziane H., Mathis C., Bales K. R., Paul S. M., Ungerer A.: Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav. Neurosci., 1999;113:982-990
41. Dodart J. C., Meziane H., Mathis C., Bales K. R., Paul S. M., Ungerer A.: Memory and learning impairment precede amyloid deposition in the V717F PDAPP transgenic mouse. Neurosci. Abstr., 1997;23:1637
42. Duff K., Eckman C., Zehr C., Yu X., Prada C. M., Perez-tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M. N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S.: Increased amyloid-β42 (43) in brains of mice expressing mutant presenilin 1. Nature, 1996;383:710-713
43. Elder G. A., Gama Sosa M. A., De Gasperi R.: Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med., 2010;77:69-81
44. Eriksen J. L., Janus C. G.: Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet., 2007;37:79-100
45. Ferri C. P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P. R., Rimmer E., Scazufca M., Alzheimer's Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet, 2005;366:2112-2117
46. Flood D. G., Lin Y. G., Lang D. M., Trusko S. P., Hirsch J. D., Savage M. J., Scott R. W., Howland D. S.: A transgenic rat model of Alzheimer's disease with extracellular Aβ deposition. Neurobiol. Aging, 2009;30:1078-1090
47. Francis B. M., Yang J., Hajderi E., Brown M. E., Michalski B., McLaurin J., Fahnestock M., Mount H. T.: Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease. Neuropsychopharmacology, 2012 (w druku)
48. Fukumoto H., Rosene D. L., Moss M. B., Raju S., Hyman B. T., Irizarry M. C.: β-secretase activity increases with aging in human, monkey, and mouse brain. Am. J. Pathol., 2004;164:719-725
49. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnsonwood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoyazavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature, 1995;373:523-527
50. Games D., Buttini M., Kobayashi D., Schenk D., Seubert P.: Mice as models: transgenic approaches and Alzheimer's disease. J. Alzheimers Dis., 2006;9(Suppl. 3):133-149
51. Georgakopoulos A., Xu J., Xu C., Mauger G., Barthet G., Robakis N. K.: Presenilin1/γ-secretase promotes the EphB2-induced phosphorylation of ephrinB2 by regulating phosphoprotein associated with glycosphingolipid-enriched microdomains/Csk binding protein. FASEB J., 2011;25:3594-3604
52. Gerlai R., Fitch T., Bales K. R., Gitter B. D.: Behavioral impairment of APP (V717F) mice in fear conditioning: is it only cognition? Behav. Brain Res., 2002;136:503-509
53. Geula C., Mesulam M. M.: Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. W: Terry R. D., Katzman R., Bick K. L. (red.) Alzheimer's Disease. New York: Raven Press, 1994;263-294
54. Glenner G. G., Wong C. W.: Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun., 1984;122:1131-1135
55. Gómez-Isla T., Hollister R., West H., Mui S., Growdon J. H., Petersen R. C., Parisi J. E., Hyman B. T.: Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol., 1997;41:17-24
56. Gordon M. N., King D. L., Diamond D. M., Jantzen P. T., Boyett K. V., Hope C. E., Hatcher J. M., Di Carlo G., Gottschall W. P., Morgan D., Arendash G. W.: Correlation between cognitive deficits and Aβ deposits in transgenic APP+PS1 mice. Neurobiol. Aging, 2001;22:377-385
57. Götz J., Chen F., Barmettler R., Nitsch R. M.: Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem., 2001;276:529-534
58. Götz J., Chen F., van Dorpe J., Nitsch R. M.: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ 42 fibrils. Science, 2001;293:1491-1495
59. Götz J., Probst A., Spillantini M. G., Schäfer T., Jakes R., Bürki K., Goedert M.: Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J., 1995;14:1304-1313
60. Hardy J.: Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci., 1997;20:154-159
61. Hardy J., Selkoe D. J.: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002;297:353-356
62. Herzig M. C., Winkler D. T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S. D., Danner S., Abramowski D., Stürchler-Pierrat C., Bürki K., van Duinen S. G., Maat-Schieman M. L., Staufenbiel M., Mathews P. M., Jucker M.: Aβ is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci., 2004;7:954-960
63. Holcomb L., Gordon M. N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C. M., Eckman C., Younkin S., Hsiao K., Duff K.: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med., 1998;4:97-100
64. Holcomb L. A., Gordon M. N., Jantzen P., Hsiao K., Duff K., Morgan D.: Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet., 1999;29:177-185
65. Hsia A. Y., Masliah E., McConlogue L., Yu G. Q., Tatsuno G., Hu K., Kholodenko D., Malenka R. C., Nicoll R. A., Mucke L.: Plaqueindependent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA, 1999;96:3228-3233
66. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G.: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science, 1996;274:99-102
67. Huang X. G., Yee B. K., Nag S., Chan S. T., Tang F.: Behavioral and neurochemical characterization of transgenic mice carrying the human presenilin-1 gene with or without the leucine-to-proline mutation at codon 235. Exp. Neurol., 2003;183:673-681
68. Huitrón-Reséndiz S., Sánchez-Alavez M., Gallegos R., Berg G., Crawford E., Giacchino J. L., Games D., Henriksen S. J., Criado J. R.: Age-independent and age-related deficits in visuospatial learning, sleep-wake states, thermoregulation and motor activity in PDAPP mice. Brain Res., 2002;928:126-137
69. Hutton M., Lendon C. L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R. C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J. M., Nowotny P., Che L. K., Norton J., Morris J. C., Reed L. A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P. R., Hayward N., Kwok J. B., Schofield P. R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B. A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P.: Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998;393:702-705
70. Ikeda M., Shoji M., Kawarai T., Kawarabayashi T., Matsubara E., Murakami T., Sasaki A., Tomidokoro Y., Ikarashi Y., Kuribara H., Ishiguro K., Hasegawa M., Yen S. H., Chishti M. A., Harigaya Y., Abe K., Okamoto K., St. George-Hyslop P., Westaway D.: Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am. J. Pathol., 2005;166:521-531
71. Irizarry M. C., Soriano F., McNamara M., Page K. J., Schenk D., Games D., Hyman B. T.: Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci., 1997;17:7053-7059
72. Ishizawa T., Sahara N., Ishiguro K., Kersh J., McGowan E., Lewis J., Hutton M., Dickson D. W., Yen S. H.: Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am. J. Pathol., 2003;163:1057-1067
73. Jackson G. R., Wiedau-Pazos M., Sang T. K., Wagle N., Brown C. A., Massachi S., Geschwind D. H.: Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron, 2002;34:509-519
74. Jacobsen J. S., Wu C. C., Redwine J. M., Comery T. A., Arias R., Bowlby M., Martone R., Morrison J. H., Pangalos M. N., Reinhart P. H., Bloom F. E.: Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006;103:5161-5166
75. Janus C.: Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn. Mem., 2004;11:337-346
76. Janus C., D'Amelio S., Amitay O., Chishti M. A., Strome R., Fraser P., Carlson G. A., Roder J. C., St George-Hyslop P., Westaway D.: Spatial learning in transgenic mice expressing human presenilin 1 (PS1) transgenes. Neurobiol. Aging, 2000;21:541-549
77. Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., Chishti M. A., Horne P., Heslin D., French J., Mount H. T., Nixon R. A., Mercken M., Bergeron C., Fraser P. E., St George-Hyslop P., Westaway D.: Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000;408:979-982
78. Justice A., Motter R.: Behavioral characterization of PDAPP transgenic Alzheimer mice. Soc. Neurosci. Abstr., 1997;23:1637
79. Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H., Younkin S. G.: Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci., 2001;21:372-381
80. Kelly P. H., Bondolfi L., Hunziker D., Schlecht H. P., Carver K., Maguire E., Abramowski D., Wiederhold K. H., Sturchler-Pierrat C., Jucker M., Bergmann R., Staufenbiel M., Sommer B.: Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol. Aging, 2003;24:365-378
81. Kelly P. H., Hunziker D., Schlecht H. P., Carver K., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Sommer B.: Progressive behavioural impairment in amyloid precursor protein transgenic mouse line APP23. Abstr. Soc. Neurosci., 1999;25:519
82. Kim J., Chang A., Dudak A., Federoff H. J., Lim S. T.: Characterization of nectin processing mediated by presenilin-dependent γ-secretase. J. Neurochem., 2011;119:945-956
83. Kobayashi D. T., Chen K. S.: Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease. Genes Brain Behav., 2005;4:173-196
84. Kotilinek L. A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B. T., Younkin S., Ashe K. H.: Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci., 2002;22:6331-6335
85. Kumar-Singh S., Dewachter I., Moechars D., Lübke U., De Jonghe C., Ceuterick C., Checler F., Naidu A., Cordell B., Cras P., Van Broeckhoven C., Van Leuven F.: Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol. Dis., 2000;7:9-22
86. Lalonde R., Dumont M., Staufenbiel M., Sturchler-Pierrat C., Strazielle C.: Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res., 2002;956:36-44
87. Lalonde R., Lewis T. L., Strazielle C., Kim H., Fukuchi K.: Transgenic mice expressing the βAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. Brain Res., 2003;977:38-45
88. Larson M. E., Lesné S. E.: Soluble Aβ oligomer production and toxicity. J. Neurochem., 2012;120(Suppl. 1):125-139
89. Lee H. G., Casadesus G., Zhu X., Takeda A., Perry G., Smith M. A.: Challenging the amyloid cascade hypothesis: senile plaques and amyloid-β as protective adaptations to Alzheimer disease. Ann. N. Y. Acad. Sci., 2004;1019:1-4
90. Lee V. M., Goedert M., Trojanowski J. Q.: Neurodegenerative tauopathies. Annu. Rev. Neurosci., 2001;24:1121-1159
91. Lesné S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., Ashe K. H.: A specific amyloid-β protein assembly in the brain impairs memory. Nature, 2006;440:352-357
92. Lesné S., Kotilinek L., Ashe K. H.: Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function. Neuroscience, 2008;151:745-749
93. Lewis J., Dickson D. W., Lin W. L., Chisholm L., Corral A., Jones G., Yen S. H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E.: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 2001;293:1487-1491
94. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W. L., Yen S. H., Dickson D. W., Davies P., Hutton M.: Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet., 2000;25:402-405
95. Lim G. P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K. H., Frautschy S. A., Cole G. M.: Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci., 2000;20:5709-5714
96. Link C. D.: Invertebrate models of Alzheimer's disease. Genes Brain Behav., 2005;4:147-156
97. Liu L., Tapiola T., Herukka S. K., Heikkilá M., Tanila H.: Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. Neuroreport, 2003;14:163-166
98. Lovasic L., Bauschke H., Janus C.: Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease. Genes Brain Behav., 2005;4:197-208
99. Masliah E., Sisk A., Mallory M., Games D.: Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J. Neuropathol. Exp. Neurol., 2001;60:357-368
100. McCool M. F., Varty G. B., Del Vecchio R. A., Kazdoba T. M., Parker E. M., Hunter J. C., Hyde L. A.: Increased auditory startle response and reduced prepulse inhibition of startle in transgenic mice expressing a double mutant form of amyloid precursor protein. Brain Res., 2003;994:99-106
101. Morgan D.: Immunotherapy for Alzheimer's disease. J. Alzheimers Dis., 2006;9(Suppl.3):425-432
102. Morgan D.: Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem. Res., 2003;28:1029-1034
103. Morgan D., Diamond D. M., Gottschall P. E., Ugen K. E., Dickey C., Hardy J., Duff K., Jantzen P., Di Carlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G. W.: Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000;408:982-985
104. Mori T., Rezai-Zadeh K., Koyama N., Arendash G. W., Yamaguchi H., Kakuda N., Horikoshi-Sakuraba Y., Tan J., Town T.: Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J. Biol. Chem., 2012;287:6912-6927
105. Morrison J. H., Hof P. R.: Life and death of neurons in the aging brain. Science, 1997;278:412-419
106. Mustafiz T., Portelius E., Gustavsson M. K., Hölttä M., Zetterberg H., Blennow K., Nordberg A., Lithner C. U.: Characterization of the brain β-amyloid isoform pattern at different ages of Tg2576 mice. Neurodegener. Dis., 2011;8:352-363
107. Neumeister K. L., Riepe M. W.: Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis., 2012;30(2):245-51
108. Nilsberth C., Westlind-Danielsson A., Eckman C. B., Condron M. M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D. B., Younkin S. G., Naslund J., Lannfelt L.: The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nat. Neurosci., 2001;4:887-893
109. Oddo S., Billings L., Kesslak J. P., Cribbs D. H., La Ferla F. M.: Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004;43:321-332
110. Oddo S., Caccamo A., Kitazawa M., Tseng B. P., La Ferla F. M.: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging, 2003;24:1063-1070
111. Oddo S., Caccamo A., Shepherd J. D., Murphy M. P., Golde T. E., Kayed R., Metherate R., Mattson M. P., Akbari Y., La Ferla F. M.: Tripletransgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron, 2003;39:409-421
112. Oddo S., Caccamo A., Tran L., Lambert M. P., Glabe C. G., Klein W. L., La Ferla F. M.: Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. J. Biol. Chem., 2006;281:1599-1604
113. Palop J. J., Jones B., Kekonius L., Chin J., Yu G. Q., Raber J., Masliah E., Mucke L.: Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. USA, 2003;100:9572-9577
114. Pappolla M. A., Chyan Y. J., Omar R. A., Hsiao K., Perry G., Smith M. A., Bozner P.: Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol., 1998;152:871-877
115. Patel N. V., Gordon M. N., Connor K. E. Good R. A., Engelman R. W., Mason J., Morgan D. G., Morgan T. E., Finch C. E.: Caloric restriction attenuates Aβ - deposition in Alzheimer transgenic models. Neurobiol. Aging, 2005;26:995-1000
116. Pennanen L., Welzl H., D'Adamo P., Nitsch R. M., Götz J.: Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol. Dis., 2004;15:500-509
117. Philipson O., Hammarström P., Nilsson K. P., Portelius E., Olofsson T., Ingelsson M., Hyman B. T., Blennow K., Lannfelt L., Kalimo H., Nilsson L. N.: A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiol. Aging, 2009;30:1393-1405
118. Polydoro M., Acker C. M., Duff K., Castillo P. E., Davies P.: Agedependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci., 2009;29:10741-10749
119. Pratt K. G., Zhu P., Watari H., Cook D. G., Sullivan J. M.: A novel role for γ-secretase: selective regulation of spontaneous neurotransmitter release from hippocampal neurons. J. Neurosci., 2011;31:899-906
120. Price D. L., Tanzi R. E., Borchelt D. R., Sisodia S. S.: Alzheimer's disease: genetic studies and transgenic models. Annu. Rev. Genet., 1998;32:461-493
121. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., Santa Cruz K., Guimaraes A., Yue M., Lewis J., Carlson G., Hutton M., Ashe K. H.: Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci., 2005;25:10637-10647
122. Redwine J. M., Kosofsky B., Jacobs R. E., Games D., Reilly J. F., Morrison J. H., Young W. G., Bloom F. E.: Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc. Natl. Acad. Sci. USA, 2003;100:1381-1386
123. Reed M. N., Hofmeister J. J., Jungbauer L., Welzel A. T., Yu C., Sherman M. A., Lesné S., La Du M. J., Walsh D. M., Ashe K. H., Cleary J. P.: Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol. Aging, 2011;32:1784-1794
124. Ribé E. M., Pérez M., Puig B., Gich I., Lim F., Cuadrado M., Sesma T., Catena S., Sánchez B., Nieto M., Gómez-Ramos P., Morán M. A., Cabodevilla F., Samaranch L., Ortiz L., Pérez A., Ferrer I., Avila J., Gómez-Isla T.: Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiol. Dis., 2005;20:814-822
125. Rizzu P., Joosse M., Ravid R., Hoogeveen A., Kamphorst W., van Swieten J. C., Willemsen R., Heutink P.: Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. Hum. Mol. Genet., 2000;9:3075-3082
126. Rogers D. C., Fisher E. M., Brown S. D., Peters J., Hunter A. J., Martin J. E.: Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm. Genome, 1997;8:711-713
127. Romberg C., Mattson M. P., Mughal M. R., Bussey T. J., Saksida L. M.: Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J. Neurosci., 2011;31:3500-3507
128. Rönnbäck A., Sagelius H., Bergstedt K. D., Näslund J., Westermark G. T., Winblad B., Graff C.: Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. Neurobiol. Aging, 2012;33:831.e11-831.e19
129. Rönnbäck A., Zhu S., Dillner K., Aoki M., Lilius L., Näslund J., Winblad B., Graff C.: Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model. Neurobiol. Aging, 2011;32:280-292
130. Röskam S., Neff F., Schwarting R., Bacher M., Dodel R.: APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. Neurosci. Biobehav. Rev., 2010;34:487-499
131. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., De Ture M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K. H.: Tau suppression in a neurodegenerative mouse model improves memory function. Science, 2005;309:476-481
132. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P.: Immunization with amyloid-β attenuates Alzheimerdisease-like pathology in the PDAPP mouse. Nature, 1999;400:173-177
133. Seabrook G. R., Smith D. W., Bowery B. J., Easter A., Reynolds T., Fitzjohn S. M., Morton R. A., Zheng H., Dawson G. R., Sirinathsinghji D. J., Davies C. H., Collingridge G. L., Hill R. G.: Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology, 1999;38:349-359
134. Senechal Y., Kelly P. H., Dev K. K.: Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning. Behav. Brain Res., 2008;186:126-132
135. Shen J., Bronson R. T., Chen D. F., Xia W., Selkoe D. J., Tonegawa S.: Skeletal and CNS defects in presenilin-1-deficient mice. Cell, 1997;89:629-639
136. Steinbach J. P., Müller U., Leist M., Li Z. W., Nicotera P., Aguzzi A.: Hypersensitivity to seizures in β-amyloid precursor protein deficient mice. Cell Death Differ., 1998;5:858-866
137. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K. H., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P. A., Waridel C., Calhoun M. E., Jucker M., Probst A., Staufenbiel M., Sommer B.: Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA, 1997;94:13287-13292
138. Subramanian S., Ayala P., Wadsworth T. L., Harris C. J., Vandenbark A. A., Quinn J. F., Offner H.: CCR6: a biomarker for Alzheimer's-like disease in a triple transgenic mouse model. J. Alzheimers Dis., 2010;22:619-629
139. Swerdlow N. R., Paulsen J., Braff D. L., Butters N., Geyer M. A., Swenson M. R.: Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J. Neurol. Neurosurg. Psychiatry, 1995;58:192-200
140. Tanemura K., Murayama M., Akagi T., Hashikawa T., Tominaga T., Ichikawa M., Yamaguchi H., Takashima A.: Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J. Neurosci., 2002;22:133-141
141. Tatebayashi Y., Miyasaka T., Chui D. H., Akagi T., Mishima K., Iwasaki K., Fujiwara M., Tanemura K., Murayama M., Ishiguro K., Planel E., Sato S., Hashikawa T., Takashima A.: Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. Proc. Natl. Acad. Sci. USA, 2002;99:13896-13901
142. Tomidokoro Y., Harigaya Y., Matsubara E., Ikeda M., Kawarabayashi T., Shirao T., Ishiguro K., Okamoto K., Younkin S. G., Shoji M.: Brain Abeta amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau. J. Pathol., 2001;194:500-506
143. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F., De Deyn P. P.: Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur. J. Neurosci., 2003;17:388-396
144. Weidemann A., Paliga K., Dürrwang U., Czech C., Evin G., Masters C. L., Beyreuther K.: Formation of stable complexes between two Alzheimer's disease gene products: presenilin 2 and β-amyloid precursor protein. Nat. Med., 1997;3:328-332
145. Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G., Ashe K. H.: The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci., 2002;22:1858-1867
146. Whitehouse P. J., Price D. L., Struble R. G., Clark A. W., Coyle J. T., Delon M. R.: Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982;215:1237-1239
147. Wilde M.: Genetic counselling. Alzheimer's disease: advances in genetics. Nurs. Stand., 1992;6:29-31
148. Wong T. P., Debeir T., Duff K., Cuello A. C.: Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci., 1999;19:2706-2716
149. Wu Y., Luo Y.: Transgenic C. elegans as a model in Alzheimer's research. Curr. Alzheimer Res., 2005;2:37-45
150. Xiong Z. M., Kitagawa K., Nishiuchi Y., Kimura T., Nakamura T., Inagaki C.: Acetyl-Ile-Gly-Leu protects neurons from Aβ1-42 induced toxicity in vitro and in V337M human tau-expressing mice. Life Sci., 2009;84:132-138
151. Yu H., Saura C. A., Choi S. Y., Sun L. D., Yang X., Handler M., Kawarabayashi T., Younkin L., Fedeles B., Wilson M. A., Younkin S., Kandel E. R., Kirkwood A., Shen J.: APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron, 2001;31:713-726
152. Yue M., Hanna A., Wilson J., Roder H., Janus C.: Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiol. Aging, 2011;32:590-603
153. Zhang J., Gorostiza O. F., Tang H., Bredesen D. E., Galvan V.: Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience. Behav. Brain Res., 2010;206:202-207
154. Zheng H., Jiang M., Trumbauer M. E., Sirinathsinghji D. J., Hopkins R., Smith D. W., Heavens R. P., Dawson G. R., Boyce S., Conner M. W., Stevens K. A., Slunt H. H., Sisoda S. S., Chen H. Y., Van der Ploeg L. H.: β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell, 1995;81:525-531
155. Zhu X., Raina A. K., Perry G., Smith M. A.: Alzheimer's disease: the two-hit hypothesis. Lancet Neurol., 2004;3:219-226